EP1926474A1 - Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability - Google Patents
Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeabilityInfo
- Publication number
- EP1926474A1 EP1926474A1 EP06783360A EP06783360A EP1926474A1 EP 1926474 A1 EP1926474 A1 EP 1926474A1 EP 06783360 A EP06783360 A EP 06783360A EP 06783360 A EP06783360 A EP 06783360A EP 1926474 A1 EP1926474 A1 EP 1926474A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- heparin
- composition
- drug
- dmso
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000035699 permeability Effects 0.000 title abstract description 13
- 238000010521 absorption reaction Methods 0.000 title description 26
- 239000002904 solvent Substances 0.000 title description 22
- 239000013583 drug formulation Substances 0.000 title description 10
- 230000002708 enhancing effect Effects 0.000 title description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 195
- 229940079593 drug Drugs 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 45
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003960 organic solvent Substances 0.000 claims abstract description 16
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960003964 deoxycholic acid Drugs 0.000 claims abstract description 15
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims abstract description 9
- 239000005711 Benzoic acid Substances 0.000 claims abstract description 8
- 235000010233 benzoic acid Nutrition 0.000 claims abstract description 8
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 79
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 56
- 229920000669 heparin Polymers 0.000 claims description 54
- 229960002897 heparin Drugs 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 36
- 150000004676 glycans Chemical class 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 19
- 229920001282 polysaccharide Polymers 0.000 claims description 19
- 239000005017 polysaccharide Substances 0.000 claims description 19
- 239000003858 bile acid conjugate Substances 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 239000013011 aqueous formulation Substances 0.000 claims description 10
- 239000003613 bile acid Substances 0.000 claims description 10
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 7
- 230000010100 anticoagulation Effects 0.000 claims description 6
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 6
- 102000055006 Calcitonin Human genes 0.000 claims description 5
- 108060001064 Calcitonin Proteins 0.000 claims description 5
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 229960004015 calcitonin Drugs 0.000 claims description 5
- 229940125396 insulin Drugs 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 102000007474 Multiprotein Complexes Human genes 0.000 claims description 3
- 108010085220 Multiprotein Complexes Proteins 0.000 claims description 3
- 229930182558 Sterol Natural products 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000003432 sterols Chemical class 0.000 claims description 3
- 235000003702 sterols Nutrition 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 230000001268 conjugating effect Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000001965 increasing effect Effects 0.000 abstract description 15
- 230000000536 complexating effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000000113 differential scanning calorimetry Methods 0.000 description 6
- -1 glycerol- polyethylene glycol ricinoleate Chemical compound 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002628 heparin derivative Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 238000005192 partition Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 238000009830 intercalation Methods 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000004434 industrial solvent Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- DKPMWHFRUGMUKF-UHFFFAOYSA-N (3alpha,5alpha,6alpha,7alpha)-3,6,7-Trihydroxycholan-24-oic acid Natural products OC1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DKPMWHFRUGMUKF-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- HVYWMOMLDIMFJA-VEIPTCAHSA-N (3r,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1C=C2C[C@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-VEIPTCAHSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- JOYGXTIHTHBSOA-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-thiophen-2-ylprop-2-en-1-one Chemical compound C1=CC(Cl)=CC=C1C(=O)C=CC1=CC=CS1 JOYGXTIHTHBSOA-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 229940093475 2-ethoxyethanol Drugs 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
- KXGVEGMKQFWNSR-DNZDVJRKSA-N 3alpha,12beta-Dihydroxy-5alpha-cholan-24-oic Acid Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@H](O)C1 KXGVEGMKQFWNSR-DNZDVJRKSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108010015031 Glycochenodeoxycholic Acid Proteins 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Chemical class 0.000 description 1
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
- 241000322338 Loeseliastrum Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108010079943 Pentagastrin Proteins 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 108010012944 Tetragastrin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical group O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 239000002416 angiotensin derivative Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical class N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- QYIXCDOBOSTCEI-NWKZBHTNSA-N coprostanol Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-NWKZBHTNSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical class [H]C#C* 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- GHCZAUBVMUEKKP-GYPHWSFCSA-N glycochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-GYPHWSFCSA-N 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 238000000892 gravimetry Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920003063 hydroxymethyl cellulose Chemical class 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Chemical class 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- RUDATBOHQWOJDD-DNMBCGTGSA-N isoursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-DNMBCGTGSA-N 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001592 luteinising effect Effects 0.000 description 1
- PGXWDLGWMQIXDT-UHFFFAOYSA-N methylsulfinylmethane;hydrate Chemical compound O.CS(C)=O PGXWDLGWMQIXDT-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000006715 negative regulation of smooth muscle cell proliferation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960000444 pentagastrin Drugs 0.000 description 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- RGYLYUZOGHTBRF-BIHRQFPBSA-N tetragastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)CCSC)C(N)=O)C1=CC=CC=C1 RGYLYUZOGHTBRF-BIHRQFPBSA-N 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UTLSPDKDSA-N ursocholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-UTLSPDKDSA-N 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- GHCZAUBVMUEKKP-UHFFFAOYSA-N ursodeoxycholic acid glycine-conjugate Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)CC2 GHCZAUBVMUEKKP-UHFFFAOYSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
Definitions
- This invention relates to drug formulations containing solubilizers for increasing solubility, absorption, and permeability of the drug. More particularly, this invention relates to mixtures and complexes of a drug and a solubilizer, wherein the solubilizer increases the water solubility of the drug and the absorption and permeability of the drug through the intestinal mucosa into the bloodstream.
- drugs are not available in oral formulations because of poor or insufficient solubility, absorption through the intestinal mucosa, and/or permeability of the drug.
- Illustrative examples of such drugs include polysaccharides, proteins, polysaccharide conjugates, protein conjugates, and protein complexes, and mixtures thereof.
- An illustrative example of a polysaccharide drug comprises heparin, and illustrative examples of protein drugs comprise insulin and calcitonin.
- heparin is a polysaccharide composed of sulfated D-glucosamine and
- heparin D-glucuronic acid residues. Due to its numerous ionizable sulfate groups, heparin possesses a strong electronegative charge. It is also a relatively strong acid that readily forms water-soluble salts, e.g. heparin sodium. It is found in mast cells and can be extracted from many body organs, particularly those with abundant mast cells. The liver and lungs are especially rich in heparin. The circulating blood contains no heparin except after profound disruption of mast cells. Heparin has many physiological roles, such as blood anticoagulation, inhibition of smooth muscle cell proliferation, and so forth. In particular, heparin is a potent anticoagulant agent that interacts strongly with antithrombin III to prevent the formation of fibrin clots.
- heparin In vivo, however, applications of heparin are very limited. Because of its hydrophilicity and high negative charge, heparin is not absorbed efficiently from the GI tract, nasal or buccal mucosal layers, and the like. Therefore, the only routes of administration used clinically are intravenous and subcutaneous injections.
- U.S. Patent No. 6,245,753 and U.S. Patent No. 6,656,922 disclose amphiphilic heparin derivatives, that is, hydrophobized heparin conjugates wherein bile acids, sterols, alkanoic acids, and the like are conjugated to heparin for increasing the hy- drophobicity of the very hydrophilic heparin molecule.
- Increasing the hydrophobicity of heparin by bonding a hydrophobic agent thereto results in what may be termed an amphiphilic heparin derivative or a hydrophobic heparin derivative. Either term is proper because the heparin derivative has increased hydrophobicity as compared to native heparin, and the heparin derivative.
- heparin-DOCA Since heparin cannot penetrate the intestinal bilayer because of its low partition coefficient and diffusivity in tissues, heparin-DOCA was synthesized by conjugation of heparin and deoxycholic acid for oral delivery. Heparin-DOCA was expected to interact readily with intestinal membranes, as well have a high partition coefficient in tissues. However, heparin-DOCA did not exhibit high absorption in the intestine due to its amphiphilicity. There was a problem that Amphiphilic heparin-DOCA made self- assembled particles due to hydrophobic interactions between the conjugated DOCA molecules under aqueous conditions, so that it decreased the absorption.
- the inventors of the present invention conducting researches aimed at enhancing the absorption of the drugs, polysaccharides such as haparin, proteins such as insulin and calcitonin, etc. through the intestinal mucosa have found that the drugs can be used as oral formulations because solubility, absorption, and permeability of the drugs can be enhanced when the drugs contain a water-miscible solubilizer, and completed this invention.
- the drug formulations according to the present invention contain a solubilizer for enhancing solubility, absorption, and permeability, they can be used as oral formulations.
- FlG. 1 shows FT-IR analysis of DMSO bound to a heparin-DOCA conjugate: heparin (solid line); DMSO-bound heparin-DOCA (10%; dotted line); DMSO-bound heparin-DOCA (30%, dashed line).
- FTG. 2 shows a TGA profile of DMSO-bound heparin-DOCA: heparin (solid line) ;
- DMSO-bound heparin (long-dashed line); heparin-DOCA (short-dashed line); DMSO- bound heparin-DOCA (dotted line).
- FTG. 3 shows a DSC profile of DMSO-bound heparin-DOCA: heparin (solid line);
- DMSO-bound heparin (long-dashed line); heparin-DOCA (short-dashed line); DMSO- bound heparin-DOCA (dotted line).
- FTG. 4 shows oral absorption of DMSO-bound heparin-DOCA in mice: heparin-
- DOCA in 10% DMSO formulation (•); DMSO-bound heparin-DOCA ( ⁇ ); DMSO- bound heparin (A).
- FTG. 5 shows absorption of DMSO-bound heparin-DOCA in capsule in monkeys when taken orally: 100 mg/kg heparin in buffer (•); 5 mg/kg DMSO-bound heparin- DOCA in capsule ( ⁇ ); 10 mg/kg DMSO-bound heparin-DOCA in capsule (A).
- FTG. 6 shows an absorption profile of DMSO-bound heparin-DOCA in monkeys when taken orally: heparin in buffer (100 mg/kg; •); heparin-DOCA in buffer (10 mg/ kg; ⁇ ); DMSO-bound heparin in buffer (10 mg/kg; A); DMSO-bound heparin-DOCA in buffer (5 mg/kg; T); DMSO-bound heparin in buffer (5 mg/kg; ⁇ ).
- An illustrative embodiment of the present invention comprises a composition comprising an aqueous mixture, complex, or combination of a mixture and a complex of a drug and a water-miscible organic solvent.
- Illustrative examples of such drugs include polysaccharides, proteins, polysaccharide conjugates, protein conjugates, and protein complexes, and mixtures thereof.
- An illustrative example of a polysaccharide drug comprises heparin
- illustrative examples of protein drugs comprise insulin and calcitonin.
- heparin-bile acid conjugates and insulin- or calcitonin-bile acid conjugates are illustrative examples of polysaccharide conjugates and protein conjugates, respectively.
- water-miscible organic solvents include dimethyl sulfoxide, N-methylpyrrolidone, polyoxyl 35 castor oil, diethylene glycol monoethyl ether, benzoic acid, and mixtures thereof.
- Another illustrative embodiment of the invention comprises a composition formed by a process comprising:
- Still another illustrative embodiment of the present invention comprises a method of treating a condition in a warm-blooded animal in need of treatment therefor, the method comprising orally administered a composition comprising a mixture, a complex, or a combination of a mixture and a complex of a drug and a water-miscible organic solvent.
- the composition can comprise an aqueous solution or a dried form.
- Yet another illustrative embodiment of the invention comprises a composition comprising a mixture, a complex, or a combination of a mixture and a complex of heparin and dimethyl sulfoxide.
- a still further illustrative example of the present invention comprises a method of treating a patient in need of anticoagulation therapy, the method comprising orally administering a safe and effective amount of a composition comprising a mixture, a complex, or a combination of a mixture and a complex of a heparin-bile acid conjugate and dimethyl sulfoxide.
- Heparin-deoxycholic acid conjugate is an illustrative example of such a heparin-bile acid conjugate.
- an illustrative embodiment of the present invention comprises a method of making an oral formulation for anticoagulation therapy, the method comprising:
- This method can optionally further comprise evaporating the aqueous formulation to dryness and encapsulating or tableting the dried aqueous formulation.
- the method can further comprise encapsulating the aqueous formulation.
- DMSO dimethyl sulfoxide
- NMP means ⁇ f-methyl pyrrolidone
- polyoxyl 35 castor oil is a nonionic solubilizer and emulsifier produced by causing ethylene oxide to react with pharmaceutical grade castor oil in a molar ratio of 35:1.
- the main component of polyoxyl 35 castor oil is glycerol- polyethylene glycol ricinoleate, which, together with fatty acid esters of polyethyleneglycol, represents the hydrophobic part of the product.
- the smaller, hy- drophilic part comprises polyethylene glycols and ethoxylated glycerol.
- Polyoxyl 35 castor oil has a hydrophilic-lipophilic balance (HLB) between 12 and 14.
- DOCA deoxycholic acid
- heparin-DOCA means a conjugate of heparin and deoxycholic acid
- protein means peptides of any length and includes polypeptides and oligopeptides. In other words, “protein” is used herein without any particular intended size limitation, unless a particular size is otherwise stated.
- Typical of proteins that can be used in the present invention are those selected from group consisting of oxytocin, vasopressin, adrenocorticotrophic hormone, epidermal growth factor, prolactin, luliberin or luteinising hormone releasing hormone, growth hormone, growth hormone releasing factor, insulin, somatostatin, glucagon, interferon, gastrin, tetragastrin, pentagastrin, urogastroine, secretin, calcitonin, enkephalins, endorphins, angiotensins, renin, bradykinin, bacitracins, polymixins, colistins, tyrocidin, gramicidines, and synthetic analogues, modifications
- polysaccharide means a carbohydrate containing more than three monosaccharide units per molecule, the units being attached to each other by glycoside linkages.
- Illustrative polysaccharides include heparin, heparin sodium, sulfonated polysaccharides, cellulose, hydroxymethylcellulose, and hydroxypropylcellulose.
- Bile acids means natural and synthetic derivatives of the steroid, cholanic acid, including, without limitation, cholic acid, deoxycholic acid, chen- odeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, isour- sodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid, gly- codeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid, hyodeoxycholic acid, and mixtures thereof, and the like.
- sterols means alcohols structurally related to the steroids including, without limitation, cholestanol, coprostanol, cholesterol, epicholesterol, ergosterol, ergocalciferol, and mixtures thereof, and the like.
- alkanoic acids means saturated fatty acids of about 4 to 20 carbon atoms.
- Illustrative alkanoic acids include, without limitation, butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, and mixtures thereof, and the like.
- an effective amount means an amount of a pharmacologically active agent that is nontoxic but sufficient to provide the desired local or systemic effect and performance at a reasonable benefit/risk ratio attending any medical treatment.
- an effective amount of a heparin-DOCA conjugate is an amount sufficient to provide a selected level of anticoagulation activity.
- safe and effective amount refers to the quantity of a component which is sufficient to yield a desired response without undue adverse effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this invention.
- the specific "safe and effective amount” will, obviously, vary with such factors as the particular condition that is being treated, the severity of the condition, the duration of the treatment, the physical condition of the patient, the nature of concurrent therapy (if any), and the specific formulation used in the present invention.
- the instant technology relates to binding water-miscible solubilizers to drugs by secondary interactions, such as intermolecular or intramolecular hydrogen bonding, hydrophobic interaction, and the like to control the solubility of such drugs in aqueous environments.
- heparin-DOCA chemical conjugate of heparin and deoxycholic acid
- heparin-DOCA is not effectively absorbed in the intestine because it cannot be dissolved in the gastrointestinal (GI) tract.
- the solubility of heparin-DOCA in aqueous solution is greatly increased, thereby significantly enhancing its absorption in the GI tract. Therefore, the present invention significantly increases drug solubility and absorption in the intestine because of the effects of the bound solubilizer molecules.
- the present technology uses a very small amount of solubilizer, the final product can be prepared as in powder form, which can be formulated as tablet or capsule type. Also, the toxicity of the solubilizer is negligible du to the small amount necessary to achieve the effect.
- heparin-DOCA Since heparin cannot penetrate the intestinal bilayer because of its low partition coefficient and diffusivity in tissues, heparin-DOCA was synthesized by conjugation of heparin and deoxycholic acid for oral delivery. Heparin-DOCA was expected to interact readily with intestinal membranes, as well have a high partition coefficient in tissues. However, heparin-DOCA did not exhibit high absorption in the intestine due to its amphiphilicity. Amphiphilic heparin-DOCA made self-assembled particles under aqueous conditions, because of hydrophobic interactions between the conjugated DOCA molecules.
- Dimethyl sulfoxide (CAS No. 67-68-5, DMSO, (CH ) SO) is an important industrial solvent as well as being widely used in biology as a cryoprotector in the de- naturation of proteins and as a drug carrier across cell membranes. Merck Index, Monograph No. 3285, 573 (13 th ed. 2001); D. Martin & H.G. Hauthal, Dimethyl Suphoxide (Wiley, New York 1975). Its broad range of properties is closely related to its properties in water solutions. DMSO mixes with water at all proportions. The partial negative charge on the oxygen atom of the DMSO molecule favors the formation of hydrogen bonds with water molecules, giving rise to strongly nonideal behavior of the mixture.
- NMP (CAS No. 872-50-4) is a dipolar aprotic solvent, which is commercially prepared by condensation of butryolactone with methylamine. It is an industrial solvent used primarily in the extraction of aromatics from lubrication oils, but also has use in other applications, such as recovery and purification of acetylenes, olefins and diolefins, gas purification, aromatics extraction from feedstocks, and a polymer solvent. NMP is miscible with water, as well as with alcohol, ether, acetone, ethyl acetate, chloroform, and benzene. Merck Index, Monograph no. 6140, 1090 (13 ed. 2001).
- Diethylene glycol monoethyl ether (CAS No. 111-90-0), also known as l-(2-ethoxyethoxy)ethanol and carbitol is a water-miscible solvent, which is prepared from ethylene oxide and 2-ethoxy-ethanol in the presence of SO . It is also miscible with acetone, benzene, chloroform, ethanol, ether, pyridine, and the like. It is used as a solvent for cellulose esters and in lacquer and thinner formulations, in quick-drying varnishes and enamels, and for dye-stuffs and wood stains. Merck Index, Monograph No. 1809, 302 (13 th ed. 2001).
- Benzoic acid (CAS No. 65-85-0) is readily soluble in water, as well as in a variety of other solvents, such as alcohol, carbon tetrachloride, chloroform, ether, acetone, benzene, carbon disulfide, and the like. Benzoic acid is used for preserving foods, fats, fruit juices, and alkaloidal solutions; in the manufacture of benzoates, benzoyl compounds, and dyes; as a mordant in calico printing; for curing tobacco; and as an antifungal. Merck Index, Monograph 1092, 187 (13 th ed. 2001).
- heparin-DOCA heparin-deoxycholic acid conjugate
- DOCA ⁇ f-hydroxylsuccinimide
- DCC dicyclohexylcarbodiimide
- Activated DOCA was then conjugated with heparin, and the resulting heparin-DOCA conjugate was purified by reverse phase and phenyl-Sepharose chromatography.
- purified heparin-DOCA was freeze dried at -80 °C to result in a white powder.
- heparin-DOCA conjugate was dissolved in 10%, 30%, 50%, 70% and 90% aqueous DMSO solution, respectively.
- heparin-DOCA 100 mg was dissolved in five aliquots each of 500 D of distilled water. To each aliquot 1, 3, 5, 7, or 9 ml of DMSO was added. The resulting solutions were dispersed by sonication with a probe-type sonicator. Finally, distilled water was added to each solution to make a final volume of 10 D, and these solutions were well mixed before freeze drying at -80 °C for 3 days to obtain a white powder.
- the resulting preparations contained DMSO molecules and DMSO/water complexes bonded to the hydroxyl groups of the heparin- DOCA conjugate, as well as simple mixtures of DMSO, DMSO/water complexes, and heparin.
- Example 1 The procedure of Example 1 was repeated except that ⁇ f-methyl pyrrolidone (NMP) was substituted for DMSO.
- NMP ⁇ f-methyl pyrrolidone
- Example 1 The procedure of Example 1 was repeated except that diethylene glycol monoethyl ether was substituted for DMSO.
- Example 1 The procedure of Example 1 was repeated except that benzoic acid was substituted for DMSO.
- Protein-bile acid conjugates were chemically synthesized. Namely, insulin-de- oxycholic acid, insulin-lithocholic acid, insulin-cholic acid, calcitonin-deoxycholic acid, calcitonin-bis deoxycholic acid, and calcitonin-tris deoxycholic acid were synthesized according to methods well known in the art. These protein-bile acid conjugates were separately mixed with DMSO, polyoxyl 35 castor oil, N - methylpyrrolidone, diethyleneglycol monoethylether, and benzoic acid at 10%, 30%, 50%, 70%, and 90% organic solvent concentrations and then were freeze dried at -80 °C for 3 days.
- TGA thermal gravimetry analysis
- DSC differential scanning calorimetry
- TGA determines the mass change of a sample as a function of temperature or time.
- FIG. 2 shows the results of the TGA experiment, wherein the total weight of DMSO- bound heparin-DOCA was changed at increasing temperatures by the evaporation of DMSO.
- DSC is a technique for measuring the energy necessary to establish a nearly zero temperature difference between a substance and an inert reference material, as the two substances are subjected to identical temperature regimes in an environment heated or cooled at a controlled rate.
- FIG. 3 shows the results of the DSC experiment, wherein peaks present for heparin-DOCA disappeared when DMSO was present.
- DMSO molecules may be bound or simply mixed with macromolecules.
- the binding of DMSO molecules to macromolecules may change the conformation of the macromolecules from a more ordered form to an amorphous form.
- DMSO molecules incorporated into the heparin-DOCA conjugates appears to affect the aggregate formation of amphiphilic heparin-DOCA and may reduce the crys- tallinity of heparin-DOCA.
- DOCA can be changed by the evaporation of DMSO molecule.
- DSC profile will be differed by the change of the heparin-DOCA structure intercalating of DMSO molecules. From the DSC and TGA results, we found that DMSO molecules are bound or mixed with macromolecules. Therefore, by the binding of DMSO molecules, the structure of heparin-DOCA might be changed to the amorphous form. From the below figures, we observed that specific peaks of heparin-DOCA gradually disappeared by the incorporation of DMSO molecules [95]
- DMSO-bound heparin-DOCA was dissolved in distilled water, and it was determined that particles of DMSO-bound heparin-DOCA were not formed under these conditions. Accordingly, aqueous solutions of DMSO-bound heparin-DOCA were orally administered to mice (5 mg/kg) FlG. 4 shows that the absorption of DMSO-bound heparin-DOCA was significantly increased as compared to the absorption of DMSO-bound heparin. Further the bioavailability of DMSO-bound heparin-DOCA was not reduced as compared to heparin-DOCA in 10% aqueous DMSO.
- DMSO-bound heparin-DOCA prepared according to the method of Example 1 was encapsulated and then administered orally to monkeys at either 5 mg/kg or 10 mg/kg dosages.
- heparin in buffer was orally administered at 100 mg/kg.
- FlG. 5 shows that absorption of heparin was negligible, however, absorption of DMSO-bound heparin-DOCA was substantial and increased according to dosage.
- aqueous formulations of heparin, heparin-DOCA, DMSO-bound heparin, and DMSO-bound heparin-DOCA were orally administered to monkeys.
- FlG. 6 shows that DMSO-bound heparin-DOCA at 5 mg/kg and 10 mg/kg dosages resulted in better absorption than any of the controls, namely, heparin (100 mg/kg), heparin-DOCA (10 mg/kg), and DMSO-bound heparin (10 mg/kg). Therefore, aqueous formulations of DMSO-bound heparin-DOCA are absorbed after oral administration, just as encapsulated powders are absorbed after oral administration (e.g., Example 11).
- the drug formulations according to the present invention contain a solubilizer for enhancing solubility, absorption, and permeability, they can be used as oral formulations.
Abstract
Solubility, absortion, and permeability of drugs upon oral administration are improved when the drugs are mixed and/or complexed with water-miscible organic solvents. Illustratively, the absortion of a heparin-deoxycholic acid conjugate upon oral administration is increased by mixing and/or complexing this conjugate with dimethyl sulfoxide. Other illustrative water-miscible organic solvents include N-methypyrrolidone, polyoxyl 35 castor oil, diethylene glycol monoethyl ether, and benzoic acid.
Description
Description
DRUG FORMULATION CONTAINING A SOLUBILIZER FOR ENHANCING SOLUBILITY, ABSORPTION, AND PERMEABILITY
Technical Field
[1] This invention relates to drug formulations containing solubilizers for increasing solubility, absorption, and permeability of the drug. More particularly, this invention relates to mixtures and complexes of a drug and a solubilizer, wherein the solubilizer increases the water solubility of the drug and the absorption and permeability of the drug through the intestinal mucosa into the bloodstream.
[2]
Background Art
[3] Since oral formulations are highly desirable for many reasons relating to convenience and cost, it would be advantageous to develop drug formulations that exhibit increased solubility, absorption, and permeability.
[4] However, many drugs are not available in oral formulations because of poor or insufficient solubility, absorption through the intestinal mucosa, and/or permeability of the drug. Illustrative examples of such drugs include polysaccharides, proteins, polysaccharide conjugates, protein conjugates, and protein complexes, and mixtures thereof. An illustrative example of a polysaccharide drug comprises heparin, and illustrative examples of protein drugs comprise insulin and calcitonin.
[5] For example, heparin is a polysaccharide composed of sulfated D-glucosamine and
D-glucuronic acid residues. Due to its numerous ionizable sulfate groups, heparin possesses a strong electronegative charge. It is also a relatively strong acid that readily forms water-soluble salts, e.g. heparin sodium. It is found in mast cells and can be extracted from many body organs, particularly those with abundant mast cells. The liver and lungs are especially rich in heparin. The circulating blood contains no heparin except after profound disruption of mast cells. Heparin has many physiological roles, such as blood anticoagulation, inhibition of smooth muscle cell proliferation, and so forth. In particular, heparin is a potent anticoagulant agent that interacts strongly with antithrombin III to prevent the formation of fibrin clots. In vivo, however, applications of heparin are very limited. Because of its hydrophilicity and high negative charge, heparin is not absorbed efficiently from the GI tract, nasal or buccal mucosal layers, and the like. Therefore, the only routes of administration used clinically are intravenous and subcutaneous injections.
[6]
[7] U.S. Patent No. 6,245,753 and U.S. Patent No. 6,656,922 disclose amphiphilic heparin derivatives, that is, hydrophobized heparin conjugates wherein bile acids, sterols, alkanoic acids, and the like are conjugated to heparin for increasing the hy- drophobicity of the very hydrophilic heparin molecule. Increasing the hydrophobicity of heparin by bonding a hydrophobic agent thereto results in what may be termed an amphiphilic heparin derivative or a hydrophobic heparin derivative. Either term is proper because the heparin derivative has increased hydrophobicity as compared to native heparin, and the heparin derivative.
[8] Since heparin cannot penetrate the intestinal bilayer because of its low partition coefficient and diffusivity in tissues, heparin-DOCA was synthesized by conjugation of heparin and deoxycholic acid for oral delivery. Heparin-DOCA was expected to interact readily with intestinal membranes, as well have a high partition coefficient in tissues. However, heparin-DOCA did not exhibit high absorption in the intestine due to its amphiphilicity. There was a problem that Amphiphilic heparin-DOCA made self- assembled particles due to hydrophobic interactions between the conjugated DOCA molecules under aqueous conditions, so that it decreased the absorption.
[9]
[10] Accordingly, the inventors of the present invention conducting researches aimed at enhancing the absorption of the drugs, polysaccharides such as haparin, proteins such as insulin and calcitonin, etc. through the intestinal mucosa have found that the drugs can be used as oral formulations because solubility, absorption, and permeability of the drugs can be enhanced when the drugs contain a water-miscible solubilizer, and completed this invention.
[H]
Disclosure of Invention Technical Problem
[12] It is an object of the present invention to provide a drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability.
[13]
Technical Solution
[14] It is a feature of the present invention to provide drug formulations comprising a mixture, a complex, or a combination of a mixture and a complex of a drug and a solubilizer, wherein the solubility, absorption, and permeability of the drug are increased upon oral administration.
[15]
Advantageous Effects
[16] Since the drug formulations according to the present invention contain a solubilizer
for enhancing solubility, absorption, and permeability, they can be used as oral formulations.
[17]
Brief Description of the Drawings
[18] FlG. 1 shows FT-IR analysis of DMSO bound to a heparin-DOCA conjugate: heparin (solid line); DMSO-bound heparin-DOCA (10%; dotted line); DMSO-bound heparin-DOCA (30%, dashed line).
[ 19] FTG. 2 shows a TGA profile of DMSO-bound heparin-DOCA: heparin (solid line) ;
DMSO-bound heparin (long-dashed line); heparin-DOCA (short-dashed line); DMSO- bound heparin-DOCA (dotted line).
[20] FTG. 3 shows a DSC profile of DMSO-bound heparin-DOCA: heparin (solid line);
DMSO-bound heparin (long-dashed line); heparin-DOCA (short-dashed line); DMSO- bound heparin-DOCA (dotted line).
[21] FTG. 4 shows oral absorption of DMSO-bound heparin-DOCA in mice: heparin-
DOCA in 10% DMSO formulation (•); DMSO-bound heparin-DOCA (■); DMSO- bound heparin (A).
[22] FTG. 5 shows absorption of DMSO-bound heparin-DOCA in capsule in monkeys when taken orally: 100 mg/kg heparin in buffer (•); 5 mg/kg DMSO-bound heparin- DOCA in capsule (■); 10 mg/kg DMSO-bound heparin-DOCA in capsule (A).
[23] FTG. 6 shows an absorption profile of DMSO-bound heparin-DOCA in monkeys when taken orally: heparin in buffer (100 mg/kg; •); heparin-DOCA in buffer (10 mg/ kg; ■); DMSO-bound heparin in buffer (10 mg/kg; A); DMSO-bound heparin-DOCA in buffer (5 mg/kg; T); DMSO-bound heparin in buffer (5 mg/kg; ♦).
[24]
Best Mode for Carrying Out the Invention
[25] An illustrative embodiment of the present invention comprises a composition comprising an aqueous mixture, complex, or combination of a mixture and a complex of a drug and a water-miscible organic solvent. Illustrative examples of such drugs include polysaccharides, proteins, polysaccharide conjugates, protein conjugates, and protein complexes, and mixtures thereof. An illustrative example of a polysaccharide drug comprises heparin, and illustrative examples of protein drugs comprise insulin and calcitonin. Similarly, heparin-bile acid conjugates and insulin- or calcitonin-bile acid conjugates are illustrative examples of polysaccharide conjugates and protein conjugates, respectively. Illustrative examples of water-miscible organic solvents according to the present invention include dimethyl sulfoxide, N-methylpyrrolidone, polyoxyl 35 castor oil, diethylene glycol monoethyl ether, benzoic acid, and mixtures thereof.
[26] Another illustrative embodiment of the invention comprises a composition formed by a process comprising:
[27] (a) mixing a drug and a water-miscible organic solvent in an aqueous solution to form a mixture; and
[28] (b) evaporating the mixture to dryness.
[29] Still another illustrative embodiment of the present invention comprises a method of treating a condition in a warm-blooded animal in need of treatment therefor, the method comprising orally administered a composition comprising a mixture, a complex, or a combination of a mixture and a complex of a drug and a water-miscible organic solvent. The composition can comprise an aqueous solution or a dried form.
[30] Yet another illustrative embodiment of the invention comprises a composition comprising a mixture, a complex, or a combination of a mixture and a complex of heparin and dimethyl sulfoxide.
[31] A still further illustrative example of the present invention comprises a method of treating a patient in need of anticoagulation therapy, the method comprising orally administering a safe and effective amount of a composition comprising a mixture, a complex, or a combination of a mixture and a complex of a heparin-bile acid conjugate and dimethyl sulfoxide. Heparin-deoxycholic acid conjugate is an illustrative example of such a heparin-bile acid conjugate.
[32] Further yet, an illustrative embodiment of the present invention comprises a method of making an oral formulation for anticoagulation therapy, the method comprising:
[33] (a) conjugating heparin to a bile acid to form a heparin-bile acid conjugate; and
[34] (b) mixing the heparin-bile acid conjugate with an aqueous solution of a water- miscible organic solvent to form an aqueous formulation.
[35] This method can optionally further comprise evaporating the aqueous formulation to dryness and encapsulating or tableting the dried aqueous formulation. Alternatively, the method can further comprise encapsulating the aqueous formulation.
[36]
[37] Before the present drug formulations for increasing solubility, absorption, and permeability of the drug are disclosed and described, it is to be understood that this invention is not limited to the particular configurations, process steps, and materials disclosed herein as such configurations, process steps, and materials may vary somewhat. It is also to be understood that the terminology employed herein is used for the purpose of describing particular embodiments only and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims and equivalents thereof.
[38] The publications and other reference materials referred to herein to describe the background of the invention and to provide additional detail regarding its practice are
hereby incorporated by reference. The references discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention.
[39] It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a drug formulation containing "a drug" includes a mixture of two or more drugs, reference to "a solubilizer" includes reference to one or more of such solubilizers, and reference to "a bile acid" includes reference to a mixture of two or more bile acids.
[40] In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below.
[41] As used herein, "comprising", "concluding", "containing", "characterized by", and grammatical equivalents thereof are inclusive or open-ended terms that do not exclude additional, unrecited elements or method steps. "Comprising" is to be interpreted as including the more restrictive terms "consisting of and "consisting essentially of. As used herein, "consisting of and grammatical equivalents thereof exclude any element, step, or ingredient not specified in the claim. As used herein, "consisting essentially of and grammatical equivalents thereof limit the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic or characteristics of the claimed invention.
[42] As used herein, "DMSO" means dimethyl sulfoxide, and "NMP" means Λf-methyl pyrrolidone.
[43] As used herein, "polyoxyl 35 castor oil" is a nonionic solubilizer and emulsifier produced by causing ethylene oxide to react with pharmaceutical grade castor oil in a molar ratio of 35:1. The main component of polyoxyl 35 castor oil is glycerol- polyethylene glycol ricinoleate, which, together with fatty acid esters of polyethyleneglycol, represents the hydrophobic part of the product. The smaller, hy- drophilic part comprises polyethylene glycols and ethoxylated glycerol. Polyoxyl 35 castor oil has a hydrophilic-lipophilic balance (HLB) between 12 and 14.
[44] As used herein, "DOCA" means deoxycholic acid, and "heparin-DOCA" means a conjugate of heparin and deoxycholic acid.
[45] As used herein, "protein" means peptides of any length and includes polypeptides and oligopeptides. In other words, "protein" is used herein without any particular intended size limitation, unless a particular size is otherwise stated. Typical of proteins that can be used in the present invention are those selected from group consisting of oxytocin, vasopressin, adrenocorticotrophic hormone, epidermal growth factor, prolactin, luliberin or luteinising hormone releasing hormone, growth hormone, growth
hormone releasing factor, insulin, somatostatin, glucagon, interferon, gastrin, tetragastrin, pentagastrin, urogastroine, secretin, calcitonin, enkephalins, endorphins, angiotensins, renin, bradykinin, bacitracins, polymixins, colistins, tyrocidin, gramicidines, and synthetic analogues, modifications and pharmacologically active fragments thereof, monoclonal antibodies and soluble vaccines. The only limitation to the protein or peptide drug that may be used in the present invention is functionality.
[46] As used herein, "polysaccharide" means a carbohydrate containing more than three monosaccharide units per molecule, the units being attached to each other by glycoside linkages. Illustrative polysaccharides include heparin, heparin sodium, sulfonated polysaccharides, cellulose, hydroxymethylcellulose, and hydroxypropylcellulose.
[47] As used herein, "bile acids" means natural and synthetic derivatives of the steroid, cholanic acid, including, without limitation, cholic acid, deoxycholic acid, chen- odeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, isour- sodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid, gly- codeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid, hyodeoxycholic acid, and mixtures thereof, and the like.
[48] As used herein, "sterols" means alcohols structurally related to the steroids including, without limitation, cholestanol, coprostanol, cholesterol, epicholesterol, ergosterol, ergocalciferol, and mixtures thereof, and the like.
[49] As used herein, "alkanoic acids" means saturated fatty acids of about 4 to 20 carbon atoms. Illustrative alkanoic acids include, without limitation, butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, and mixtures thereof, and the like.
[50] As used herein, "effective amount" means an amount of a pharmacologically active agent that is nontoxic but sufficient to provide the desired local or systemic effect and performance at a reasonable benefit/risk ratio attending any medical treatment. Thus, for example, an effective amount of a heparin-DOCA conjugate is an amount sufficient to provide a selected level of anticoagulation activity.
[51] As used herein, the term "safe and effective amount" refers to the quantity of a component which is sufficient to yield a desired response without undue adverse effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this invention. The specific "safe and effective amount" will, obviously, vary with such factors as the particular condition that is being treated, the severity of the condition, the duration of the treatment, the physical condition of the patient, the nature of concurrent therapy (if any), and the specific formulation used in the present invention.
[52] The instant technology relates to binding water-miscible solubilizers to drugs by secondary interactions, such as intermolecular or intramolecular hydrogen bonding,
hydrophobic interaction, and the like to control the solubility of such drugs in aqueous environments. For example, the chemical conjugate of heparin and deoxycholic acid (heparin-DOCA) was developed for the oral delivery of heparin. U.S. Patent No. 6,245,753; U.S. Patent No. 6,656,922. However, heparin-DOCA is not effectively absorbed in the intestine because it cannot be dissolved in the gastrointestinal (GI) tract. On the other hand, when dimethylsulfoxide (DMSO) molecules, for example, are bound to heparin-DOCA, the solubility of heparin-DOCA in aqueous solution is greatly increased, thereby significantly enhancing its absorption in the GI tract. Therefore, the present invention significantly increases drug solubility and absorption in the intestine because of the effects of the bound solubilizer molecules. In particular, since the present technology uses a very small amount of solubilizer, the final product can be prepared as in powder form, which can be formulated as tablet or capsule type. Also, the toxicity of the solubilizer is negligible du to the small amount necessary to achieve the effect.
[53] Since heparin cannot penetrate the intestinal bilayer because of its low partition coefficient and diffusivity in tissues, heparin-DOCA was synthesized by conjugation of heparin and deoxycholic acid for oral delivery. Heparin-DOCA was expected to interact readily with intestinal membranes, as well have a high partition coefficient in tissues. However, heparin-DOCA did not exhibit high absorption in the intestine due to its amphiphilicity. Amphiphilic heparin-DOCA made self-assembled particles under aqueous conditions, because of hydrophobic interactions between the conjugated DOCA molecules.
[54] By the binding of organic molecules (dimethyl sulfoxide or N-methyl pyrrolidone, for example) to protein or polysaccharide, it is possible to change the molecular conformation of these molecules, which actually was changed quite freely in aqueous condition. Organic molecules intercalated in protein or polysaccharide affect the formation of aggregates formed by hydrophobic or ionic interactions. Therefore, randomly intercalating organic molecule in proteins or polysaccharides can block the formation of molecular aggregation or the interactions between molecules, thereby sol- ubilizing such molecules in aqueous solution. For example, because of intercalating DMSO molecules, DMSO-bound heparin-DOCA conjugate do not self-aggregate in aqueous solution, thereby completely dissolving in aqueous media.
[55] Dimethyl sulfoxide (CAS No. 67-68-5, DMSO, (CH ) SO) is an important industrial solvent as well as being widely used in biology as a cryoprotector in the de- naturation of proteins and as a drug carrier across cell membranes. Merck Index, Monograph No. 3285, 573 (13th ed. 2001); D. Martin & H.G. Hauthal, Dimethyl Suphoxide (Wiley, New York 1975). Its broad range of properties is closely related to its properties in water solutions. DMSO mixes with water at all proportions. The
partial negative charge on the oxygen atom of the DMSO molecule favors the formation of hydrogen bonds with water molecules, giving rise to strongly nonideal behavior of the mixture. Molecular dynamics results show that DMSO typically forms two hydrogen bonds with water molecules, although other configurations may also form. Hydrogen bonds between DMSO and water molecules are longer lived than water-water hydrogen bonds. A. Luzar & D. Chandler, Structure and hydrogen bond dynamics of water-dimethyl sulfoxide mixtures by computer simulations, 98 J. Chem. Phys. 8160-8173 (1993). The interaction between DMSO and water molecules is stronger than the interaction between water and the polar head group of a phospholipid membrane. S.N. Shashkov et al., The study of DMSO/water and DPPC/DMSO/water system by means of X-ray, neutron small angle scattering, calorimetry, and IR spectroscopy, 271 Physical B 184-191 (1999).
[56] NMP (CAS No. 872-50-4) is a dipolar aprotic solvent, which is commercially prepared by condensation of butryolactone with methylamine. It is an industrial solvent used primarily in the extraction of aromatics from lubrication oils, but also has use in other applications, such as recovery and purification of acetylenes, olefins and diolefins, gas purification, aromatics extraction from feedstocks, and a polymer solvent. NMP is miscible with water, as well as with alcohol, ether, acetone, ethyl acetate, chloroform, and benzene. Merck Index, Monograph no. 6140, 1090 (13 ed. 2001).
[57] Diethylene glycol monoethyl ether (CAS No. 111-90-0), also known as l-(2-ethoxyethoxy)ethanol and carbitol is a water-miscible solvent, which is prepared from ethylene oxide and 2-ethoxy-ethanol in the presence of SO . It is also miscible with acetone, benzene, chloroform, ethanol, ether, pyridine, and the like. It is used as a solvent for cellulose esters and in lacquer and thinner formulations, in quick-drying varnishes and enamels, and for dye-stuffs and wood stains. Merck Index, Monograph No. 1809, 302 (13th ed. 2001).
[58] Benzoic acid (CAS No. 65-85-0) is readily soluble in water, as well as in a variety of other solvents, such as alcohol, carbon tetrachloride, chloroform, ether, acetone, benzene, carbon disulfide, and the like. Benzoic acid is used for preserving foods, fats, fruit juices, and alkaloidal solutions; in the manufacture of benzoates, benzoyl compounds, and dyes; as a mordant in calico printing; for curing tobacco; and as an antifungal. Merck Index, Monograph 1092, 187 (13th ed. 2001).
[59]
Mode for the Invention
[60] <Example 1>
[61] A heparin-deoxycholic acid conjugate (heparin-DOCA) was prepared according to
the method described in U.S. Patent No. 6,656,922. Briefly, DOCA was activated by reaction with Λf-hydroxylsuccinimide (HOSu) and dicyclohexylcarbodiimide (DCC). Activated DOCA was then conjugated with heparin, and the resulting heparin-DOCA conjugate was purified by reverse phase and phenyl-Sepharose chromatography. Finally, purified heparin-DOCA was freeze dried at -80 °C to result in a white powder.
[62] Next, aliquots of heparin-DOCA conjugate were dissolved in 10%, 30%, 50%, 70% and 90% aqueous DMSO solution, respectively. Briefly, heparin-DOCA (100 mg) was dissolved in five aliquots each of 500 D of distilled water. To each aliquot 1, 3, 5, 7, or 9 ml of DMSO was added. The resulting solutions were dispersed by sonication with a probe-type sonicator. Finally, distilled water was added to each solution to make a final volume of 10 D, and these solutions were well mixed before freeze drying at -80 °C for 3 days to obtain a white powder. The resulting preparations contained DMSO molecules and DMSO/water complexes bonded to the hydroxyl groups of the heparin- DOCA conjugate, as well as simple mixtures of DMSO, DMSO/water complexes, and heparin.
[63]
[64] <Example 2>
[65] The procedure of Example 1 was repeated except that Λf-methyl pyrrolidone (NMP) was substituted for DMSO.
[66]
[67] <£xample 3>
[68] The procedure of Example 1 was repeated except that polyoxyl 35 castor oil
(CREMOPHOR®EL; BASF) was substituted for DMSO.
[69]
[70] <£xample 4>
[71] The procedure of Example 1 was repeated except that diethylene glycol monoethyl ether was substituted for DMSO.
[72]
[73] <£xample 5>
[74] The procedure of Example 1 was repeated except that benzoic acid was substituted for DMSO.
[75]
[76] <Example 6>
[77] Protein-bile acid conjugates were chemically synthesized. Namely, insulin-de- oxycholic acid, insulin-lithocholic acid, insulin-cholic acid, calcitonin-deoxycholic acid, calcitonin-bis deoxycholic acid, and calcitonin-tris deoxycholic acid were synthesized according to methods well known in the art. These protein-bile acid conjugates were separately mixed with DMSO, polyoxyl 35 castor oil, N -
methylpyrrolidone, diethyleneglycol monoethylether, and benzoic acid at 10%, 30%, 50%, 70%, and 90% organic solvent concentrations and then were freeze dried at -80 °C for 3 days.
[78] [79] Experimental Example 1> [80] To determine how many DMSO molecules were contained in heparin-DOCA samples prepared according to the procedure of Example 1, samples containing 30 mg of heparin-DOCA were weighed before and after being freeze dried. DMSO-bound heparins and DMSO-bound heparin-DOCA conjugates were prepared with various amount of DMSO molecules. As shown in Table 1, increasing the DMSO concentration resulted in increased amounts of DMSO molecules bound to heparin- DOCA. When a 50% or higher DMSO solution was used, the amount of DMSO bound to heparin-DOCA was saturated.
[81] Table 1
[82] [83] Experimental Example 2> [84] The procedure of Experimental Example 1 was repeated except that N - methylpyrrolidone, polyoxyl 35 castor oil, diethyleneglycol monoethylether, and benzoic acid were substituted for DMSO. The weight of the heparin-DOCA conjugates increased in these solvents, however, freeze drying showed that these compositions did not make self-assembled aggregates in water.
[85] [86] Experimental Example 3> [87] Fourier Transform Infrared spectroscopy (FT-IR) analysis was carried out according to methods well known in the art on heparin-DOCA samples mixed with
DMSO. FT-IR data confirmed that DMSO molecules incorporated in heparin-DOCA were merely mixed or tightly bound with heparin-DOCA conjugates. Stretch or shift bands showed by the bonds of DMSO were observed from the results of FT-IR, as shown in FIG. 1. The shift of OH- bonds in DMSO-bound heparin-DOCA was shown at 1650 cm" . The stretching C-H vibrations of heparin-DOCA was located in the region 1317 and 1420 cm"1. Also, rocking C-H bonds were observed at 950 cm"1. The strong S-O stretch band (v(S-O), DMSO) was observed at 1012-1014 cm"1. These results show that DMSO molecules were bound with heparin-DOCA conjugates as well as being merely mixed with such conjugates.
[88]
[89] Experimental Example 4>
[90] To analyze the characterization of DMSO-bound heparin-DOCA, thermal gravimetry analysis (TGA) and differential scanning calorimetry (DSC) were performed on heparin, DMSO-bound heparin, heparin-DOCA, and DMSO-bound heparin-DOCA.
[91] TGA determines the mass change of a sample as a function of temperature or time.
FIG. 2 shows the results of the TGA experiment, wherein the total weight of DMSO- bound heparin-DOCA was changed at increasing temperatures by the evaporation of DMSO.
[92] DSC is a technique for measuring the energy necessary to establish a nearly zero temperature difference between a substance and an inert reference material, as the two substances are subjected to identical temperature regimes in an environment heated or cooled at a controlled rate. FIG. 3 shows the results of the DSC experiment, wherein peaks present for heparin-DOCA disappeared when DMSO was present.
[93] These results show that DMSO molecules may be bound or simply mixed with macromolecules. The binding of DMSO molecules to macromolecules may change the conformation of the macromolecules from a more ordered form to an amorphous form. DMSO molecules incorporated into the heparin-DOCA conjugates appears to affect the aggregate formation of amphiphilic heparin-DOCA and may reduce the crys- tallinity of heparin-DOCA.
[94] According to the increase of temperature, the total weight of DMSO-bound heparin-
DOCA can be changed by the evaporation of DMSO molecule. Also, DSC profile will be differed by the change of the heparin-DOCA structure intercalating of DMSO molecules. From the DSC and TGA results, we found that DMSO molecules are bound or mixed with macromolecules. Therefore, by the binding of DMSO molecules, the structure of heparin-DOCA might be changed to the amorphous form. From the below figures, we observed that specific peaks of heparin-DOCA gradually disappeared by the incorporation of DMSO molecules
[95]
[96] Experimental Example 5>
[97] DMSO-bound heparin-DOCA was dissolved in distilled water, and it was determined that particles of DMSO-bound heparin-DOCA were not formed under these conditions. Accordingly, aqueous solutions of DMSO-bound heparin-DOCA were orally administered to mice (5 mg/kg) FlG. 4 shows that the absorption of DMSO-bound heparin-DOCA was significantly increased as compared to the absorption of DMSO-bound heparin. Further the bioavailability of DMSO-bound heparin-DOCA was not reduced as compared to heparin-DOCA in 10% aqueous DMSO.
[98]
[99] Experimental Example 6>
[100] DMSO-bound heparin-DOCA prepared according to the method of Example 1 was encapsulated and then administered orally to monkeys at either 5 mg/kg or 10 mg/kg dosages. As a control, heparin in buffer was orally administered at 100 mg/kg. FlG. 5 shows that absorption of heparin was negligible, however, absorption of DMSO-bound heparin-DOCA was substantial and increased according to dosage.
[101]
[ 102] Experimental Example 7>
[103] It was determined that DMSO-bound heparin-DOCA does not form particles, while heparin-DOCA does form particles, when dissolved or dispersed in water. In this example, aqueous formulations of heparin, heparin-DOCA, DMSO-bound heparin, and DMSO-bound heparin-DOCA were orally administered to monkeys. FlG. 6 shows that DMSO-bound heparin-DOCA at 5 mg/kg and 10 mg/kg dosages resulted in better absorption than any of the controls, namely, heparin (100 mg/kg), heparin-DOCA (10 mg/kg), and DMSO-bound heparin (10 mg/kg). Therefore, aqueous formulations of DMSO-bound heparin-DOCA are absorbed after oral administration, just as encapsulated powders are absorbed after oral administration (e.g., Example 11).
[104]
Industrial Applicability
[105] As explained hereinbefore, since the drug formulations according to the present invention contain a solubilizer for enhancing solubility, absorption, and permeability, they can be used as oral formulations.
[106]
Claims
Claims
[I] A composition comprising an aqueous mixture, complex, or combination of a mixture and a complex of a drug and a water-miscible organic solvent.
[2] The composition of claim 1 wherein the drug is a member selected from the group consisting of polysaccharides, proteins, polysaccharide conjugates, protein conjugates, and protein complexes, and mixtures thereof.
[3] The composition of claim 1 wherein the drug comprises a polysaccharide
[4] The composition of claim 1 wherein the drug comprises heparin.
[5] The composition of claim 1 wherein the drug comprises a protein.
[6] The composition of claim 1 wherein the drug comprises insulin.
[7] The composition of claim 1 wherein the drug comprises calcitonin
[8] The composition of claim 1 wherein the drug comprises a conjugate of a polysaccharide and a bile acid, sterol, or alkanoic acid. [9] The composition of claim 1 wherein the drug comprises a conjugate of heparin and a bile acid. [10] The composition of claim 9 wherein the bile acid comprises deoxycholic acid.
[II] The composition of claim 1 wherein the drug comprises a conjugate of a protein and a bile acid.
[12] The composition of claim 11 wherein the drug comprises an insulin-bile acid conjugate. [13] The composition of claim 11 wherein the drug comprises a calcitonin-bile acid conjugate. [14] The composition of claim 1 wherein the water-miscible organic solvent is a member selected from the group consisting of dimethyl sulfoxide, N - methylpyrrolidone, polyoxyl 35 castor oil, diethylene glycol monoethyl ether, benzoic acid, and mixtures thereof. [15] The composition of claim 1 wherein the water-miscible organic solvent comprises dimethyl sulfoxide. [16] A composition formed by a process comprising:
(a) mixing a drug and a water-miscible organic solvent in an aqueous solution to form a mixture ; and
(b) evaporating the mixture to dryness.
[17] The composition of claim 16 wherein the drug comprises heparin and the organic solvent comprises dimethyl sulfoxide.
[18] A method of treating a condition in a warm-blooded animal in need of treatment therefor, the method comprising orally administered a composition comprising a mixture, a complex, or a combination of a mixture and a complex of a drug and a
water-miscible organic solvent.
[19] The method of claim 18 wherein the composition comprises an aqueous solution.
[20] The method of claim 18 wherein the composition comprises a dried form.
[21] A composition comprising a mixture, a complex, or a combination of a mixture and a complex of heparin and dimethyl sulfoxide. [22] The composition of claim 21 wherein the composition comprises an aqueous solution.
[23] The composition of claim 21 wherein the composition comprises a dried form.
[24] A method of treating a patient in need of anticoagulation therapy, the method comprising orally administering a safe and effective amount of a composition comprising a mixture, a complex, or a combination of a mixture and a complex of a heparin-bile acid conjugate and dimethyl sulfoxide. [25] The method of claim 24 wherein the heparin-bile acid conjugate comprises heparin-deoxycholic acid complex. [26] A method of making an oral formulation for anticoagulation therapy, the method comprising:
(a) conjugating heparin to a bile acid to form a heparin-bile acid conjugate; and
(b) mixing the heparin-bile acid conjugate with an aqueous solution of a water- miscible organic solvent to form an aqueous formulation.
[27] The method of claim 26 wherein the heparin-bile acid conjugate comprises heparin-deoxycholic acid conjugate. [28] The method of claim 26 wherein the water-miscible organic solvent comprises dimethyl sulfoxide. [29] The method of claim 26 further comprising evaporating the aqueous formulation to dryness. [30] The method of claim 29 further comprising encapsulating or tableting the dried aqueous formulation. [31] The method of claim 26 further comprising encapsulating the aqueous formulation.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/188,217 US20070021325A1 (en) | 2005-07-21 | 2005-07-21 | Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability |
KR1020060067466A KR20070012219A (en) | 2005-07-21 | 2006-07-19 | Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability |
PCT/KR2006/002848 WO2007011171A1 (en) | 2005-07-21 | 2006-07-19 | Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1926474A1 true EP1926474A1 (en) | 2008-06-04 |
Family
ID=37669021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06783360A Withdrawn EP1926474A1 (en) | 2005-07-21 | 2006-07-19 | Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1926474A1 (en) |
WO (1) | WO2007011171A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115462369B (en) * | 2022-09-29 | 2023-09-22 | 安徽省立医院(中国科学技术大学附属第一医院) | Vitrification frozen exosome preservation method |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9021674D0 (en) * | 1990-10-05 | 1990-11-21 | Ethical Pharma Ltd | Transdermal device |
US6458383B2 (en) * | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
KR20020066778A (en) * | 2001-02-13 | 2002-08-21 | 한국과학기술연구원 | Formulation to enhance bioavailability of bioactive materials and preparation method thereof |
ES2414084T3 (en) * | 2003-02-24 | 2013-07-18 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
-
2006
- 2006-07-19 WO PCT/KR2006/002848 patent/WO2007011171A1/en active Application Filing
- 2006-07-19 EP EP06783360A patent/EP1926474A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2007011171A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007011171A1 (en) | 2007-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070021325A1 (en) | Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability | |
EP3313857B1 (en) | Polymer-cyclodextrin-lipid conjugates | |
US6656922B2 (en) | Oral delivery of macromolecules | |
CN101396563B (en) | Chitose derivates using octreotide as target ligand and use thereof in medicament | |
AU2004222439B2 (en) | Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer | |
Kim et al. | Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation | |
JPH07500084A (en) | Pharmaceutical carrier | |
WO1998000169A1 (en) | Hydrophobic preparations containing medium chain monoglycerides | |
WO2008136536A1 (en) | Hybrid gel comprising chemically cross-linked hyaluronic acid derivative, and pharmaceutical composition using the same | |
CN113264906B (en) | Docetaxel dimer micromolecular prodrug and construction of self-assembled nanoparticle thereof | |
WO2021157665A1 (en) | Hyaluronic acid derivative, pharmaceutical composition, and hyaluronic acid derivative-drug conjugate | |
WO2016209732A1 (en) | Polymer-cyclodextrin-lipid conjugates | |
US10111932B2 (en) | Coagonists of glucagon-like peptide 1 receptor and neuropeptide Y2 receptor | |
WO2007011171A1 (en) | Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability | |
CN114796513A (en) | Di-selenium bond bridged docetaxel dimer prodrug and self-assembled nanoparticles thereof | |
Kim et al. | A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study | |
EP2590682A1 (en) | Delivery of hydrophilic peptides | |
CN101357939B (en) | Protein conjugate and pharmaceutical compositions thereof | |
JP4084199B2 (en) | Process for increasing mucosal absorption of amphiphilic heparin derivatives | |
CN106860874B (en) | Carboxymethyl chitosan-rhein conjugate and synthesis process thereof | |
US20070141158A1 (en) | Amphiphilic heparin derivative formed by coupling a heparin with a bile acid | |
CN101439188B (en) | Polymer lyophilized preparation of insoluble anti-tumor medicament | |
CN110960491A (en) | Preparation method and application of tanshinone IIA-loaded water-soluble chitosan/gamma-polyglutamic acid nano-composite | |
KR20100096038A (en) | Method for preparation of nanostructured complex of hydrophobic drug | |
ITPD20090168A1 (en) | FOSPHOLIPID POLYMERIC CONJUGATES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20071221 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20081111 |